insights_auto
Why is ALKS down 2.68%?
Dive Deeperchevron_right
ALKS:NASDAQ
Alkermes Plc
$42.13
arrow_downward
-2.68%(-1.16) 1D
$41.80
arrow_downward
-0.78% (-0.33)todayPre-market
Closed: Sep 23, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$43.20
High
$43.62
Low
$41.23
Mkt. cap
7.07B
Avg. vol.
1.67M
Volume
6.42K
P/E ratio
109.47
52-wk high
$55.67
52-wk low
$26.99
EPS
$0.38
Beta
0.27
Shares outstanding
167.76M
No. of employees
2K
Open
$43.20
High
$43.62
Low
$41.23
Mkt. cap
7.07B
Avg. vol.
1.67M
Volume
6.42K
P/E ratio
109.47
52-wk high
$55.67
52-wk low
$26.99
EPS
$0.38
Beta
0.27
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
Investing.com
·
50 minutes ago
Goldman Sachs resumes Alkermes stock coverage with neutral rating
GuruFocus
·
2 hours ago
ALKS Looks 29.1% Overvalued on GF Value™
Yahoo Finance
·
1 day ago
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com